Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Leukemia, Myeloid, Acute 3Paraproteinemias 2Immunoglobulin Light-chain Amyloidosis 2Breast Neoplasms 2Stomach Neoplasms 1Recurrence 1Postoperative Complications 1Papillomavirus Infections 1Myelodysplastic Syndromes 1Intermittent Fasting 1Colorectal Neoplasms 1Advanced Hormone Receptor-Positive Breast Carcinoma 1

Interventions

Dexamethasone 13daratumumab 7Bortezomib 7Cyclophosphamide 6Calcium Dobesilate 5ixazomib 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4venetoclax 3belantamab mafodotin 3Specimen Handling 34-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 3pomalidomide 2isatuximab 2X-Rays 2Polymerase Chain Reaction 2Phantoms, Imaging 2Magnetic Resonance Spectroscopy 2Clinical Protocols 2Biopsy 2siltuximab 1Valganciclovir 1Tissue Banks 1Therapeutics 1Stem Cell Transplantation 1Spectrometry, Fluorescence 1Positron-Emission Tomography 1Pharmaceutical Preparations 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × Clinical Protocols × 1 year × Clear all
NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡